Evidence map›Paper›PMID 39588777›Full record

ArticleNucleic acids research2024

STK39-mediated amplification of γ-H2A.X promotes homologous recombination and contributes to PARP inhibitor resistance.

Yi Xu, Changying Li, Huan Yin, Somaira Nowsheen, Xin Xu, Wenjuan Kang, Xin Liu, Lifeng Chen, Zhenkun Lou, Junlin Yi and 1 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yi XuState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuan Nanli No17, Chaoyang District, Beijing 100021, China.
Changying LiState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuan Nanli No17, Chaoyang District, Beijing 100021, China.
Huan YinState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuan Nanli No17, Chaoyang District, Beijing 100021, China.
Somaira NowsheenDepartment of Dermatology, University of California San Diego, 9500 Gilman Drive, La Jolla, San Diego, CA 92122, USA.
Xin XuState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuan Nanli No17, Chaoyang District, Beijing 100021, China.
Wenjuan KangState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuan Nanli No17, Chaoyang District, Beijing 100021, China.
Xin LiuState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuan Nanli No17, Chaoyang District, Beijing 100021, China.
Lifeng ChenDepartment of Gynecology, the First Affiliated Hospital, School of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou 310003, China.
Zhenkun LouDepartment of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.ORCID 0000-0003-1938-3091
Junlin YiState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuan Nanli No17, Chaoyang District, Beijing 100021, China.
Min DengState Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuan Nanli No17, Chaoyang District, Beijing 100021, China.

Funding

Cancer Foundation of China LC2021R02Chinese Academy of Medical Sciences 2021-I2M-1-067Chinese Academy of Medical Sciences 2021-RC310-013Chinese Academy of Medical Sciences CFA202201008Medical Health Science and Technology Project of Zhejiang Provincial HealthNational High Level Hospital Clinical Research Funding 2022-CICAMS-80102022203National Science and Technology Major Project 2023ZD0502200National Science Foundation of China 82272757Peking Union Medical College 3332022028,2023-CICAMS-3332023029Zhejiang Provincial Natural Science Foundation Q22H168103
6 · The paper itself

Abstract

The phosphorylation of histone H2A.X into γH2A.X is a crucial early event in the DNA damage response, marking DNA damage sites and initiating repair processes. While ATM kinase is traditionally recognized as the primary mediator of H2A.X phosphorylation, our study identifies serine/threonine kinase 39 (STK39) as a novel enhancer of this critical signaling pathway. We demonstrate that after DNA damage, STK39 undergoes phosphorylation by the ATM kinase, facilitating its interaction with the Mre11-Rad50-Nbs1 complex and subsequent recruitment to chromatin. This recruitment enables STK39 to further phosphorylate H2A.X, thus amplifying γH2A.X production and promoting homologous recombination repair. Notably, we observe a significant upregulation of STK39 in pancreatic adenocarcinoma (PAAD) tissues, correlating with heightened resistance to PARPi therapy. Furthermore, we demonstrate the synergistic efficacy of combining STK39 inhibition with PARP inhibitors in suppressing and reversing PAAD growth. This study not only provides new insights into the molecular dynamics of H2A.X phosphorylation but also highlights the therapeutic potential of targeting STK39 to enhance PARPi sensitivity in PAAD (created with BioRender).

Indexed as

Drug Resistance, NeoplasmHistonesPancreatic NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsProtein Serine-Threonine KinasesAcid Anhydride HydrolasesAdenocarcinomaAtaxia Telangiectasia Mutated ProteinsCell Cycle ProteinsCell Line, TumorDNA-Binding ProteinsDNA DamageHomologous RecombinationHumansMRE11 Homologue ProteinPhosphorylationAcid Anhydride HydrolasesAtaxia Telangiectasia Mutated ProteinsATM protein, humanCell Cycle ProteinsDNA-Binding ProteinsH2AX protein, humanHistonesMRE11 Homologue ProteinMRE11 protein, humanPoly(ADP-ribose) Polymerase InhibitorsProtein Serine-Threonine KinasesRAD50 protein, human

Identifiers

PMID39588777
PMCPMC11662673

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.